Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Nat Genet. Author manuscript; available in PMC 2012 February 1.
Published in final edited form as:
Published online 2011 July 17. doi:  10.1038/ng.883
PMCID: PMC3154019

NBEAL2 is mutated in Gray Platelet Syndrome and is required for biogenesis of platelet alpha-granules


Gray Platelet Syndrome (GPS) is an autosomal recessive bleeding disorder with large platelets that lack α-granules. We found that mutations of NBEAL2 (neurobeachin-like 2), encoding a BEACH/ARM/WD40 domain protein, cause GPS. We demonstrated that human megakaryocytes and platelets express a unique combination of NBEAL2 transcripts. Proteomic analysis of sucrose-gradient subcellular fractions of platelets indicated that NBEAL2 localizes to the dense tubular system (endoplasmic reticulum) in platelets.

Keywords: Gray platelet syndrome, NBEAL2, neurobeachin, platelet α-granules, organelle biogenesis

Platelets are organelle-rich cells that transport granule-bound compounds to tissues throughout the body. Platelet α-granules, the most abundant platelet organelles, store large proteins that, when released, promote platelet adhesiveness, haemostasis and wound healing1,2, while platelet dense (δ) granules contain small, non-protein molecules such as calcium, serotonin, adenosine diphosphate, adenosine triphosphate, and pyrophosphate that promote platelet aggregation1,3,4,5. Bleeding disorders arising from defective platelet granules constitute the platelet storage pool diseases (SPD) and include isolated δ -granule deficiency (delta-SPD), combined α and δ -SPD and isolated α -granule deficiency (GPS; OMIM #139090)3,4,6. GPS platelets are large and appear gray on light microscopy (Fig. 1a-b)5-7; the diagnosis is confirmed by electron microscopy (EM) showing absent or markedly reduced α-granules in platelets8(Fig. 1c-d) and in megakaryocytes9, although both platelets and megakaryocytes have rudimentary α-granule precursors10.

Figure 1
Cellular studies of gray platelet syndrome

Clinical manifestations of GPS are usually mild to moderate and infrequently severe6. GPS is also associated with myelofibrosis (Fig. 1e-f) and splenomegaly as a consequence of myelofibrosis5-7 The basis of myelofibrosis remains unknown, but constitutive release of platelet-derived growth factor and other pro-fibrotic substances from megakaryocytes into the bone marrow may be involved5.

Some platelet α-granule constituents are passively (e.g., immunoglobulins, albumin) or actively (e.g., fibrinogen) taken up from the plasma by receptor-mediated endocytosis; others are synthesized in megakaryocytes (e.g., platelet factor 4, β-thromboglobulin) and trafficked to the organelle3. In GPS, proteins synthesized in megakaryocytes are markedly reduced, while endocytosed α-granule constituents are less affected3. This suggests that GPS megakaryocytes fail to pack their endogeneously synthesized secretory proteins into developing α-granules.

By genome-wide linkage analysis and homozygosity mapping of 25 GPS patients from 14 unrelated families, we previously mapped the GPS disease locus to a 9.4 megabase interval on 3p21.1-22.1 that includes 197 protein coding genes6. Initial whole exome and Sanger dideoxy sequencing revealed no mutations in any of these genes, but subsequent Sanger dideoxy sequencing of exons not previously covered did reveal mutations in a single gene. In fact, 15 unrelated GPS patients exhibited NBEAL2 (ENSG00000160796) mutations, including 5 missense, 3 nonsense, 4 frameshifting and 3 consensus splice site mutations (Table 1, Fig. 1g, Supplementary Fig. 1 and 2). None of these variants was found in the 1000 Genomes Database (, which contained 629 genomes as of February 2011, or in 100 ethnically matched control individuals. The 14 affected individuals with identity by descent had homozygous mutations (Table 1) whereas those without identity by descent exhibited compound heterozygous mutations.

Table 1
Mutations in NBEAL2 (ENSG00000160796) in patients with Gray Platelet Syndrome*

All missense variants alter conserved amino acids and have high pathogenicity prediction scores (Supplemetary Fig. 1p). Splice donor site mutations c.1296+5G>A, c.5301+1G>A result in use of cryptic intronic donor sites demonstrated in blood mRNA, and c.5720+5G>A is predicted to obliterate a splice donor site (Supplementary Fig. 1).

Patients from families GPS-6 and GPS-8 illustrated interfamilial variability. Although each is homozygous for splice mutation c.1296+5G>C, the patient from family GPS-6 has mild coagulopathy and the patient from family GPS-8 has severe coagulopathy6. Similar findings were observed for other GPS patients; the severity of coagulopathy, myelofibrosis and splenomegaly did not correlate with the type or location of the NBEAL2 mutation (Table 1, Fig. 1g).

Human NBEAL2 is predicted to produce 15 different mRNA transcripts, of which 7 would be protein coding (Ensembl) (Supplementary Fig. 3a). We designed cDNA primers to differentially amplify all protein encoding NBEAL2 transcripts (Supplementary Fig. 3) and tested RNA from a variety of human hematopoietic cells and other tissues. A unique combination of transcripts encoding NBEAL2-001, 201/003, 203/004 and 202 was expressed in megakaryocytes and platelets (Supplementary Table 1).

Antibodies to NBEAL2 are not available. To explore the subcellular localization of NBEAL2 protein, we performed proteomic analysis on sucrose-gradient subcellular fractions from normal platelets and identified 2 tryptic peptides from the protein NBEAL2 using mass spectrometry (Fig. 1g, Supplementary Fig. 4). These peptide sequences, contained within NBEAL2 transcripts 001, 003 and 201, were found in platelet subcellular fraction 4, which contained small membrane structures on EM analysis2 that likely originated from the dense tubular system. In fact, fraction 4 was enriched in dense tubular system and ER markers (data not shown).

The fibrotic nature of the GPS bone marrow prevented us from obtaining sufficient bone marrow for ex-vivo expansion of GPS megakaryocytes, the only cell type that expresses the GPS phenotype of defective α-granule biogenesis. Our previous microarray data in GPS fibroblasts showed overexpression of fibronectin11, essential for proplatelet formation in cultured megakaryocytes12 and critical for megakaryocyte-matrix interactions13. Future studies investigating GPS megakaryocytes might shed light on the pathogenesis of the myelofibrosis in GPS.

How absence of NBEAL2 function in megakaryocytes results in defective α-granule biogenesis remains unknown. However, NBEAL2 belongs to the family of proteins that contain an ARM, BEACH (beige and Chediak-Higashi syndrome) and WD40 domains, highly conserved regions that are crucial for protein-protein interactions, membrane dynamics and vesicle trafficking14. Another such protein is CHS1, which is defective in Chediak-Higashi disease (CHD, OMIM #214500), a disorder of immunodeficiency, platelet dense granule defects, partial albinism, and enlarged lysosomes or lysosome-related organelles in hematopoietic cells and melanocytes4,15. The precise cell biological defects in GPS and CHD remain unknown, but both diseases involve large proteins and impaired formation and trafficking of intracellular vesicles. NBEAL2 protein is predicted to interact with WDFY3 (WD repeat and FYVE domain containing 3), which itself interacts with CHS1, and with DLL1 and jagged 1 (, known to have roles in hematopoiesis. DLL1 is the human homolog of the Notch Delta ligand and jagged 1 is the ligand for the receptor notch 1. These protein-protein interactions are entirely based on computational predictions; future experiments will determine their accuracy. Understanding NBEAL2 function will likely lead to the discovery of novel pathways of organelle formation and maturation.

Supplementary Material


We thank all of our GPS patients and families for their cooperation, the NIH Intramural Sequencing Center for performing the whole exome sequencing and analysis, and Dr. Alan Nurden for contributing the French patient. We appreciate the excellent technical assistance of Isa Bernardini and Roxanne Fisher and the DNA sequencing assistance of Hailey Edwards, Lauren Riley, Katie Patzel, Pranoot Tanpaiboon, Judith Chezar and Joseph Manaster. We thank Dr. Thomas Markello for SNP array and Dr. Irina Maric, Dr. Safak Gucer and Dr. Isinsu Kuzu for their assistance in bone marrow slides. This study was supported by the Intramural Research Programs of the National Human Genome Research Institute and the NIH Clinical Center and by the Israeli Ministry of Justice; Izvonot Fund, grant # 84/2004, 85/2004 and 9090-25/2007 to TCFZ.


Authorship Contributions:

M.G.-A. is the principal investigator of clinical trials NCT00069680 (Genetic Analysis of Gray Platelet Syndrome) and NCT00086476 (Investigations of Megakaryocytes from Patients with Abnormal Platelet Vesicles), M.G.-A wrote the manuscript, cultured megakaryocytes, M.G.-A, W.A.G. and T.C.F.-Z., designed and supervised research, M.G.-A, and T.C.F.-Z., and T.V., analyzed clinical and molecular data, T.C.F.-Z., is the principal investigator of the Israeli protocol “Clinical and Genetic Analysis of Gray Platelet Syndrome,” W.A.G. is the principal investigator of clinical trial NCT00369421 (Diagnosis and Treatment of Patients With Inborn Errors of Metabolism), and accountable investigator of clinical trial NCT00069680 (Genetic Analysis of Gray Platelet Syndrome), M.G.-A., T.V., T.C.F.-Z., C.J.M., and M.H. supervised DNA sequencing, M.G.-A., T.V., Y. Z.-E., F.G., M.C., M.K., N.B., N.K., Y.H., K.B., R.K., and P.C., performed DNA sequencing, M.G.-A. T.C.F.-Z., F.G., M.C., M.K., N.K., R.K., Y.A., M.A., A.S.F., B.E.K., K.J., and J.G.W., recruited patients and provided clinical data, J.G.W., performed electron microscopy, D.M., performed proteomic analysis, D.H., cultured fibroblasts, T.C.F.-Z., T.V., Y. Z.-E., F.G., M.C., M.K., N.B., N.K., Y.H., D.M., H.D., K.B., R.K., Y.A., M.A., A.S.F., B.E.K., K.J., P.C., C.J.M., J.G.W., M.H., and W.A.G. participated in preparing the manuscript.

Disclosure of Conflicts of Interest: No competing financial interests.


1. Rendu F, Brohard-Bohn B. Platelets. 2001;12:261–273. [PubMed]
2. Maynard DM, Heijnen HF, Horne MK, White JG, Gahl WA. J Thromb Haemost. 2007;5:1945–1955. [PubMed]
3. Weiss HJ, et al. Blood. 1979;54:1296–1319. [PubMed]
4. Gunay-Aygun M, Huizing M, Gahl WA. Semin Thromb Hemost. 2004;30:537–547. [PubMed]
5. Nurden AT, Nurden P. Blood Rev. 2007;21:21–36. [PubMed]
6. Gunay-Aygun M, et al. Blood. 2010;116:4990–5001. [PubMed]
7. Raccuglia G. Am J Med. 1971;51:818–828. [PubMed]
8. White JG. Am J Pathol. 1979;95:445–462. [PubMed]
9. Breton-Gorius J, Vainchenker W, Nurden A, Levy-Toledano S, Caen J. Am J Pathol. 1981;102:10–19. [PubMed]
10. Maynard DM, Heijnen HF, Gahl WA, Gunay-Aygun M. J Thromb Haemost. 2010;8:1786–1796. [PMC free article] [PubMed]
11. Hyman T, et al. Br J Haematol. 2003;122:142–149. [PubMed]
12. Jiang F, Jia Y, Cohen I. Blood. 2002;99:3579–3584. [PubMed]
13. Malara A, et al. Blood. 2010
14. Wang N, Wu WI, De Lozanne A. J Cell Biochem. 2002;86:561–570. [PubMed]
15. Kaplan J, De Domenico I, Ward DM. Curr Opin Hematol. 2008;15:22–29. [PubMed]